Use of ReliZORB for Feeding Intolerance in Critically Ill Patients
Status:
Not yet recruiting
Trial end date:
2024-01-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the use of ReliZORB improves nutrition tolerance
and helps critically ill patients meet their nutrition goals. Subjects in the intensive care
unit will be enrolled and randomized 2:1 to receive ReliZORB or placebo cartridges with
enteral feedings for 5 days. Blood and stool samples will be collected to test for nutrition
and inflammation.